PITTSBURGH, June 29, 2023 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors to perform in vivo gene editing without triggering the immune system, today announced a broad set of preclinical data, including non-human primate (“NHP”) repeat dosing data, for its…Read More
NeuBase Presents NonHuman Primate Data Illustrating Stealth Editors are NonImmunogenic Opening the Door to Redosing
